Compare PEBO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | ANAB |
|---|---|---|
| Founded | 1902 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2005 | 2015 |
| Metric | PEBO | ANAB |
|---|---|---|
| Price | $38.31 | $48.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $42.50 | ★ $87.25 |
| AVG Volume (30 Days) | 427.5K | ★ 510.1K |
| Earning Date | 10-20-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 1.59 | N/A |
| Revenue | $197,000.00 | ★ $234,603,000.00 |
| Revenue This Year | $7.39 | $17.97 |
| Revenue Next Year | $56.09 | $36.88 |
| P/E Ratio | $23.99 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $28.01 | $30.27 |
| 52 Week High | $42.29 | $73.30 |
| Indicator | PEBO | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 48.05 |
| Support Level | $37.53 | $44.43 |
| Resistance Level | $39.33 | $51.27 |
| Average True Range (ATR) | 0.71 | 2.29 |
| MACD | 0.30 | 0.44 |
| Stochastic Oscillator | 93.79 | 58.84 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).